Global Psoriasis Treatment Market – Industry Analysis and forecast (2019 to 2026) – By treatment, technology, End-use and Region

Global Psoriasis Treatment Market size is expected to grow at a CAGR of 9.3% during the forecast period and the market size is expected to reach nearly US$ 37.52 Bn. by 2026. Global Psoriasis Treatment market To know about the Research Methodology :- Request Free Sample Report Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin growth, skin patches are typically red, dry, itchy, and scaly.

Global Psoriasis Treatment Market Drivers and Restrain

Rising prevalence of the condition, heading with growing awareness, the screening and diagnosis of the disease are expected to fuel the global psoriasis treatment market in the coming years. Psoriasis treatment options also contribute to a number of side-effects such as liver and kidney damage, hypertension, and increased risk of cancer, etc., are the factors could hamper the growth of Global Psoriasis Treatment Market in forecast period.

Global Psoriasis Treatment Market key segmentation

By drug class, the global market has been categorized into TNF inhibitors, Interleukin inhibitors, Vitamin D analogs, Corticosteroids, and others. Tumour Necrosis Factor Inhibitors is further categorized as Adalimumab, Infliximab, Etanercept. Vitamin D Analogues is segmented into Calcitriol, Calcipotriol, Tacalcitol. The Interleukin inhibitors segment is projected to lead the global psoriasis treatment market during the forecast period. High market share of the interleukin inhibitors segment can be attributed to the superior efficacy and safety of drugs in this class for the treatment of psoriasis. Moreover, the acceptance of this drug class is attributable to interleukin blockers, which are considered to be a viable option for patients having trouble responding to other treatment.

Global Psoriasis Treatment Market Regional Analysis

By region, the global psoriasis market to witness dominance of North America followed by Europe. As per the National Psoriasis Foundation, there are about X million people in America living with psoriasis. Because of quick adoption of biological therapy and rise in investments on research and development for clinical trials will drive global market in this region. On the other side, the emerging markets in the Middle East and Africa, Latin America, and Asia Pacific are expected to offer growth opportunities thanks to increasing patient pool, the improving healthcare infrastructure and medical facilities. The objective of the report is to present comprehensive analysis of Global Psoriasis Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Psoriasis Treatment Market dynamics, structure by analyzing the market segments, and project the Global Psoriasis Treatment Market size. Clear representation of competitive analysis of key players by Psoriasis Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Psoriasis Treatment Market.

Scope of the Global Psoriasis Treatment Market: Inquire before buying

Global Psoriasis Treatment Market Drug class

• Corticosteroids • Tumour Necrosis Factor Inhibitors • interleukin inhibitors • Vitamin D Analogues

Global Psoriasis Treatment Market by Treatment

• Biologic Drugs • Small Molecule Systemic Drugs • Tropical Therapies

Global Psoriasis Treatment Market by Route of administration

• Oral • Parenteral • Topical

Global Psoriasis Treatment Market by region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating on Global Psoriasis Treatment Market

• AbbVie Inc., • Amgen Inc., • AstraZeneca, • Biogen, • Boehringer Ingelheim, • Celgene, • Eli Lilly and Company, • Johnson & Johnson, • LEO Pharma A/S, • Merck & Co., Inc., • Novartis AG, • Pfizer, Inc., • Stiefel Laboratories Inc. (GlaxoSmithKline plc.), • Sun Pharmaceutical Industries • Takeda Pharmaceutical Company Limited • Boeringer Ingelheim International GmbH • UCB S.A. • Cipla Inc. • Rowan Bioceuticals • Glenmark Pharmaceuticals • Win-Medicare Pvt. Ltd.

194Global Psoriasis Treatment Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Psoriasis Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Psoriasis Treatment Market Analysis and Forecast 6.1. Global Psoriasis Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Psoriasis Treatment Market Analysis and Forecast, by Treatment 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Psoriasis Treatment Market Value Share Analysis, by Treatment 7.4. Global Psoriasis Treatment Market Size (US$ Bn) Forecast, by Treatment 7.5. Global Psoriasis Treatment Market Analysis, by Treatment 7.6. Global Psoriasis Treatment Market Attractiveness Analysis, by Treatment 8. Global Psoriasis Treatment Market Analysis and Forecast, by Route of administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Psoriasis Treatment Market Value Share Analysis, by Route of administration 8.4. Global Psoriasis Treatment Market Size (US$ Bn) Forecast, by Route of administration 8.5. Global Psoriasis Treatment Market Analysis, by Route of administration 8.6. Global Psoriasis Treatment Market Attractiveness Analysis, by Route of administration 9. Global Psoriasis Treatment Market Analysis and Forecast, by Drug class 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Psoriasis Treatment Market Value Share Analysis, by Drug class 9.4. Global Psoriasis Treatment Market Size (US$ Bn) Forecast, by Drug class 9.5. Global Psoriasis Treatment Market Analysis, by Drug class 9.6. Global Psoriasis Treatment Market Attractiveness Analysis, by Drug class 10. Global Psoriasis Treatment Market Analysis, by Region 10.1. Global Psoriasis Treatment Market Value Share Analysis, by Region 10.2. Global Psoriasis Treatment Market Size (US$ Bn) Forecast, by Region 10.3. Global Psoriasis Treatment Market Attractiveness Analysis, by Region 11. North America Psoriasis Treatment Market Analysis 11.1. Key Findings 11.2. North America Psoriasis Treatment Market Overview 11.3. North America Psoriasis Treatment Market Value Share Analysis, by Treatment 11.4. North America Psoriasis Treatment Market Forecast, by Treatment 11.4.1. Biologic Drugs 11.4.2. Small Molecule Systemic Drugs 11.4.3. Tropical Therapies 11.5. North America Psoriasis Treatment Market Value Share Analysis, by Route of administration 11.6. North America Psoriasis Treatment Market Forecast, by Route of administration 11.6.1. Oral 11.6.2. Parenteral 11.6.3. Topical 11.7. North America Psoriasis Treatment Market Value Share Analysis, by Drug class 11.8. North America Psoriasis Treatment Market Forecast, by Drug class 11.8.1. Corticosteroids 11.8.2. Tumour Necrosis Factor Inhibitors 11.8.3. interleukin inhibitors 11.8.4. Vitamin D Analogues 11.9. North America Psoriasis Treatment Market Value Share Analysis, by Country 11.10. North America Psoriasis Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Psoriasis Treatment Market Analysis, by Country 11.12. U.S. Psoriasis Treatment Market Forecast, by Treatment 11.12.1. Biologic Drugs 11.12.2. Small Molecule Systemic Drugs 11.12.3. Tropical Therapies 11.13. U.S. Psoriasis Treatment Market Forecast, by Route of administration 11.13.1. Oral 11.13.2. Parenteral 11.13.3. Topical 11.14. U.S. Psoriasis Treatment Market Forecast, by Drug class 11.14.1. Corticosteroids 11.14.2. Tumour Necrosis Factor Inhibitors 11.14.3. interleukin inhibitors 11.14.4. Vitamin D Analogues 11.15. Canada Psoriasis Treatment Market Forecast, by Treatment 11.15.1. Biologic Drugs 11.15.2. Small Molecule Systemic Drugs 11.15.3. Tropical Therapies  11.16. Steel Canada Psoriasis Treatment Market Forecast, by Route of administration 11.16.1. Oral 11.16.2. Parenteral 11.16.3. Topical 11.17. Canada Psoriasis Treatment Market Forecast, by Drug class 11.17.1. Corticosteroids 11.17.2. Tumour Necrosis Factor Inhibitors 11.17.3. interleukin inhibitors 11.17.4. Vitamin D Analogues 11.18. North America Psoriasis Treatment Market Attractiveness Analysis 11.18.1. By Treatment 11.18.2. By Route of administration 11.18.3. By Drug class 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Psoriasis Treatment Market Analysis 12.1. Key Findings 12.2. Europe Psoriasis Treatment Market Overview 12.3. Europe Psoriasis Treatment Market Value Share Analysis, by Treatment 12.4. Europe Psoriasis Treatment Market Forecast, by Treatment 12.4.1. Biologic Drugs 12.4.2. Small Molecule Systemic Drugs 12.4.3. Tropical Therapies 12.5. Europe Psoriasis Treatment Market Value Share Analysis, by Route of administration 12.6. Europe Psoriasis Treatment Market Forecast, by Route of administration 12.6.1. Oral 12.6.2. Parenteral 12.6.3. Topical 12.7. Europe Psoriasis Treatment Market Value Share Analysis, by Drug class 12.8. Europe Psoriasis Treatment Market Forecast, by Drug class 12.8.1. Corticosteroids 12.8.2. Tumour Necrosis Factor Inhibitors 12.8.3. interleukin inhibitors 12.8.4. Vitamin D Analogues 12.9. Europe Psoriasis Treatment Market Value Share Analysis, by Country 12.10. Europe Psoriasis Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Psoriasis Treatment Market Analysis, by Country 12.12. Germany Psoriasis Treatment Market Forecast, by Treatment 12.12.1. Biologic Drugs 12.12.2. Small Molecule Systemic Drugs 12.12.3. Tropical Therapies 12.13. Germany Psoriasis Treatment Market Forecast, by Route of administration 12.13.1. Oral 12.13.2. Parenteral 12.13.3. Topical 12.14. Germany Psoriasis Treatment Market Forecast, by Drug class 12.14.1. Corticosteroids 12.14.2. Tumour Necrosis Factor Inhibitors 12.14.3. interleukin inhibitors 12.14.4. Vitamin D Analogues 12.15. U.K. Psoriasis Treatment Market Forecast, by Treatment 12.15.1. Biologic Drugs 12.15.2. Small Molecule Systemic Drugs 12.15.3. Tropical Therapies 12.16. U.K. Psoriasis Treatment Market Forecast, by Route of administration 12.16.1. Oral 12.16.2. Parenteral 12.16.3. Topical 12.17. U.K. Psoriasis Treatment Market Forecast, by Drug class 12.17.1. Corticosteroids 12.17.2. Tumour Necrosis Factor Inhibitors 12.17.3. interleukin inhibitors 12.17.4. Vitamin D Analogues 12.18. France Psoriasis Treatment Market Forecast, by Treatment 12.18.1. Biologic Drugs 12.18.2. Small Molecule Systemic Drugs 12.18.3. Tropical Therapies 12.19. France Psoriasis Treatment Market Forecast, by Route of administration 12.19.1. Oral 12.19.2. Parenteral 12.19.3. Topical 12.20. France Psoriasis Treatment Market Forecast, by Drug class 12.20.1. Corticosteroids 12.20.2. Tumour Necrosis Factor Inhibitors 12.20.3. interleukin inhibitors 12.20.4. Vitamin D Analogues 12.21. Italy Psoriasis Treatment Market Forecast, by Treatment 12.21.1. Biologic Drugs 12.21.2. Small Molecule Systemic Drugs 12.21.3. Tropical Therapies 12.22. Italy Psoriasis Treatment Market Forecast, by Route of administration 12.22.1. Oral 12.22.2. Parenteral 12.22.3. Topical 12.23. Italy Psoriasis Treatment Market Forecast, by Drug class 12.23.1. Corticosteroids 12.23.2. Tumour Necrosis Factor Inhibitors 12.23.3. interleukin inhibitors 12.23.4. Vitamin D Analogues 12.24. Spain Psoriasis Treatment Market Forecast, by Treatment 12.24.1. Biologic Drugs 12.24.2. Small Molecule Systemic Drugs 12.24.3. Tropical Therapies 12.25. Spain Psoriasis Treatment Market Forecast, by Route of administration 12.25.1. Oral 12.25.2. Parenteral 12.25.3. Topical 12.26. Spain Psoriasis Treatment Market Forecast, by Drug class 12.26.1. Corticosteroids 12.26.2. Tumour Necrosis Factor Inhibitors 12.26.3. interleukin inhibitors 12.26.4. Vitamin D Analogues 12.27. Rest of Europe Psoriasis Treatment Market Forecast, by Treatment 12.27.1. Biologic Drugs 12.27.2. Small Molecule Systemic Drugs 12.27.3. Tropical Therapies 12.28. Rest of Europe Psoriasis Treatment Market Forecast, by Route of administration 12.28.1. Oral 12.28.2. Parenteral 12.28.3. Topical 12.29. Rest Of Europe Psoriasis Treatment Market Forecast, by Drug class 12.29.1. Corticosteroids 12.29.2. Tumour Necrosis Factor Inhibitors 12.29.3. interleukin inhibitors 12.29.4. Vitamin D Analogues 12.30. Europe Psoriasis Treatment Market Attractiveness Analysis 12.30.1. By Treatment 12.30.2. By Route of administration 12.30.3. By Drug class 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Psoriasis Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Psoriasis Treatment Market Overview 13.3. Asia Pacific Psoriasis Treatment Market Value Share Analysis, by Treatment 13.4. Asia Pacific Psoriasis Treatment Market Forecast, by Treatment 13.4.1. Biologic Drugs 13.4.2. Small Molecule Systemic Drugs 13.4.3. Tropical Therapies 13.5. Asia Pacific Psoriasis Treatment Market Value Share Analysis, by Route of administration 13.6. Asia Pacific Psoriasis Treatment Market Forecast, by Route of administration 13.6.1. Oral 13.6.2. Parenteral 13.6.3. Topical 13.7. Asia Pacific Psoriasis Treatment Market Value Share Analysis, by Drug class 13.8. Asia Pacific Psoriasis Treatment Market Forecast, by Drug class 13.8.1. Corticosteroids 13.8.2. Tumour Necrosis Factor Inhibitors 13.8.3. interleukin inhibitors 13.8.4. Vitamin D Analogues 13.9. Asia Pacific Psoriasis Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Psoriasis Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Psoriasis Treatment Market Analysis, by Country 13.12. China Psoriasis Treatment Market Forecast, by Treatment 13.12.1. Biologic Drugs 13.12.2. Small Molecule Systemic Drugs 13.12.3. Tropical Therapies 13.13. China Psoriasis Treatment Market Forecast, by Route of administration 13.13.1. Oral 13.13.2. Parenteral 13.13.3. Topical 13.14. China Psoriasis Treatment Market Forecast, by Drug class 13.14.1. Corticosteroids 13.14.2. Tumour Necrosis Factor Inhibitors 13.14.3. interleukin inhibitors 13.14.4. Vitamin D Analogues 13.15. India Psoriasis Treatment Market Forecast, by Treatment 13.15.1. Biologic Drugs 13.15.2. Small Molecule Systemic Drugs 13.15.3. Tropical Therapies 13.16. India Psoriasis Treatment Market Forecast, by Route of administration 13.16.1. Oral 13.16.2. Parenteral 13.16.3. Topical 13.17. India Psoriasis Treatment Market Forecast, by Drug class 13.17.1. Corticosteroids 13.17.2. Tumour Necrosis Factor Inhibitors 13.17.3. interleukin inhibitors 13.17.4. Vitamin D Analogues 13.18. Japan Psoriasis Treatment Market Forecast, by Treatment 13.18.1. Biologic Drugs 13.18.2. Small Molecule Systemic Drugs 13.18.3. Tropical Therapies 13.19. Japan Psoriasis Treatment Market Forecast, by Route of administration 13.19.1. Oral 13.19.2. Parenteral 13.19.3. Topical 13.20. Japan Psoriasis Treatment Market Forecast, by Drug class 13.20.1. Corticosteroids 13.20.2. Tumour Necrosis Factor Inhibitors 13.20.3. interleukin inhibitors 13.20.4. Vitamin D Analogues 13.21. ASEAN Psoriasis Treatment Market Forecast, by Treatment 13.21.1. Biologic Drugs 13.21.2. Small Molecule Systemic Drugs 13.21.3. Tropical Therapies 13.22. ASEAN Psoriasis Treatment Market Forecast, by Route of administration 13.22.1. Oral 13.22.2. Parenteral 13.22.3. Topical 13.23. ASEAN Psoriasis Treatment Market Forecast, by Drug class 13.23.1. Corticosteroids 13.23.2. Tumour Necrosis Factor Inhibitors 13.23.3. interleukin inhibitors 13.23.4. Vitamin D Analogues 13.24. Rest of Asia Pacific Psoriasis Treatment Market Forecast, by Treatment 13.24.1. Biologic Drugs 13.24.2. Small Molecule Systemic Drugs 13.24.3. Tropical Therapies 13.25. Rest of Asia Pacific Psoriasis Treatment Market Forecast, by Route of administration 13.25.1. Oral 13.25.2. Parenteral 13.25.3. Topical 13.26. Rest of Asia Pacific Psoriasis Treatment Market Forecast, by Drug class 13.26.1. Corticosteroids 13.26.2. Tumour Necrosis Factor Inhibitors 13.26.3. interleukin inhibitors 13.26.4. Vitamin D Analogues 13.27. Asia Pacific Psoriasis Treatment Market Attractiveness Analysis 13.27.1. By Treatment 13.27.2. By Route of administration 13.27.3. By Drug class 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Psoriasis Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Psoriasis Treatment Market Overview 14.3. Middle East & Africa Psoriasis Treatment Market Value Share Analysis, by Treatment 14.4. Middle East & Africa Psoriasis Treatment Market Forecast, by Treatment 14.4.1. Biologic Drugs 14.4.2. Small Molecule Systemic Drugs 14.4.3. Tropical Therapies 14.5. Middle East & Africa Psoriasis Treatment Market Value Share Analysis, by Route of administration 14.6. Middle East & Africa Psoriasis Treatment Market Forecast, by Route of administration 14.6.1. Oral 14.6.2. Parenteral 14.6.3. Topical 14.7. Middle East & Africa Psoriasis Treatment Market Value Share Analysis, by Drug class 14.8. Middle East & Africa Psoriasis Treatment Market Forecast, by Drug class 14.8.1. Corticosteroids 14.8.2. Tumour Necrosis Factor Inhibitors 14.8.3. interleukin inhibitors 14.8.4. Vitamin D Analogues 14.9. Middle East & Africa Psoriasis Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Psoriasis Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Psoriasis Treatment Market Analysis, by Country 14.12. GCC Psoriasis Treatment Market Forecast, by Treatment 14.12.1. Biologic Drugs 14.12.2. Small Molecule Systemic Drugs 14.12.3. Tropical Therapies 14.13. GCC Psoriasis Treatment Market Forecast, by Route of administration 14.13.1. Oral 14.13.2. Parenteral 14.13.3. Topical 14.14. GCC Psoriasis Treatment Market Forecast, by Drug class 14.14.1. Corticosteroids 14.14.2. Tumour Necrosis Factor Inhibitors 14.14.3. interleukin inhibitors 14.14.4. Vitamin D Analogues 14.15. South Africa Psoriasis Treatment Market Forecast, by Treatment 14.15.1. Biologic Drugs 14.15.2. Small Molecule Systemic Drugs 14.15.3. Tropical Therapies 14.16. South Africa Psoriasis Treatment Market Forecast, by Route of administration 14.16.1. Oral 14.16.2. Parenteral 14.16.3. Topical 14.17. South Africa Psoriasis Treatment Market Forecast, by Drug class 14.17.1. Corticosteroids 14.17.2. Tumour Necrosis Factor Inhibitors 14.17.3. interleukin inhibitors 14.17.4. Vitamin D Analogues 14.18. Rest of Middle East & Africa Psoriasis Treatment Market Forecast, by Treatment 14.18.1. Biologic Drugs 14.18.2. Small Molecule Systemic Drugs 14.18.3. Tropical Therapies 14.19. Rest of Middle East & Africa Psoriasis Treatment Market Forecast, by Route of administration 14.19.1. Oral 14.19.2. Parenteral 14.19.3. Topical 14.20. Rest of Middle East & Africa Psoriasis Treatment Market Forecast, by Drug class 14.20.1. Corticosteroids 14.20.2. Tumour Necrosis Factor Inhibitors 14.20.3. interleukin inhibitors 14.20.4. Vitamin D Analogues 14.21. Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis 14.21.1. By Treatment 14.21.2. By Route of administration 14.21.3. By Drug class 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Psoriasis Treatment Market Analysis 15.1. Key Findings 15.2. South America Psoriasis Treatment Market Overview 15.3. South America Psoriasis Treatment Market Value Share Analysis, by Treatment 15.4. South America Psoriasis Treatment Market Forecast, by Treatment 15.4.1. Biologic Drugs 15.4.2. Small Molecule Systemic Drugs 15.4.3. Tropical Therapies 15.5. South America Psoriasis Treatment Market Value Share Analysis, by Route of administration 15.6. South America Psoriasis Treatment Market Forecast, by Route of administration 15.6.1. Oral 15.6.2. Parenteral 15.6.3. Topical 15.7. South America Psoriasis Treatment Market Value Share Analysis, by Drug class 15.8. South America Psoriasis Treatment Market Forecast, by Drug class 15.8.1. Corticosteroids 15.8.2. Tumour Necrosis Factor Inhibitors 15.8.3. interleukin inhibitors 15.8.4. Vitamin D Analogues 15.9. South America Psoriasis Treatment Market Value Share Analysis, by Country 15.10. South America Psoriasis Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Psoriasis Treatment Market Analysis, by Country 15.12. Brazil Psoriasis Treatment Market Forecast, by Treatment 15.12.1. Biologic Drugs 15.12.2. Small Molecule Systemic Drugs 15.12.3. Tropical Therapies 15.13. Brazil Psoriasis Treatment Market Forecast, by Route of administration 15.13.1. Oral 15.13.2. Parenteral 15.13.3. Topical 15.14. Brazil Psoriasis Treatment Market Forecast, by Drug class 15.14.1. Corticosteroids 15.14.2. Tumour Necrosis Factor Inhibitors 15.14.3. interleukin inhibitors 15.14.4. Vitamin D Analogues 15.15. Mexico Psoriasis Treatment Market Forecast, by Treatment 15.15.1. Biologic Drugs 15.15.2. Small Molecule Systemic Drugs 15.15.3. Tropical Therapies 15.16. Mexico Psoriasis Treatment Market Forecast, by Route of administration 15.16.1. Oral 15.16.2. Parenteral 15.16.3. Topical 15.17. Mexico Psoriasis Treatment Market Forecast, by Drug class 15.17.1. Corticosteroids 15.17.2. Tumour Necrosis Factor Inhibitors 15.17.3. interleukin inhibitors 15.17.4. Vitamin D Analogues 15.18. Rest of South America Psoriasis Treatment Market Forecast, by Treatment 15.18.1. Biologic Drugs 15.18.2. Small Molecule Systemic Drugs 15.18.3. Tropical Therapies 15.19. Rest of South America Psoriasis Treatment Market Forecast, by Route of administration 15.19.1. Oral 15.19.2. Parenteral 15.19.3. Topical 15.20. Rest of South America Psoriasis Treatment Market Forecast, by Drug class 15.20.1. Corticosteroids 15.20.2. Tumour Necrosis Factor Inhibitors 15.20.3. interleukin inhibitors 15.20.4. Vitamin D Analogues 15.21. South America Psoriasis Treatment Market Attractiveness Analysis 15.21.1. By Treatment 15.21.2. By Route of administration 15.21.3. By Drug class 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. AbbVie Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint, 16.3.2. Amgen Inc., 16.3.3. AstraZeneca, 16.3.4. Biogen, 16.3.5. Boehringer Ingelheim, 16.3.6. Celgene, 16.3.7. Eli Lilly and Company, 16.3.8. Johnson & Johnson, 16.3.9. LEO Pharma A/S, 16.3.10. Merck & Co., Inc., 16.3.11. Novartis AG, 16.3.12. Pfizer, Inc., 16.3.13. Stiefel Laboratories Inc. (GlaxoSmithKline plc.), 16.3.14. Sun Pharmaceutical Industries 16.3.15. Takeda Pharmaceutical Company Limited 16.3.16. Boeringer Ingelheim International GmbH 16.3.17. UCB S.A. 16.3.18. Cipla Inc. 16.3.19. Rowan Bioceuticals 16.3.20. Glenmark Pharmaceuticals 16.3.21. Win-Medicare Pvt. Ltd. 17. Primary Key Insights

About This Report

Report ID 37175
Category Healthcare
Published Date Nov 2019
Updated Date Oct 2020
Contact Us